alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
```

[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1457 Introduced in House (IH)]

109th CONGRESS
  1st Session
                                H. R. 1457

To amend the Internal Revenue Code of 1986 to restore the deduction for 
the travel expenses of a taxpayer's spouse who accompanies the taxpayer 
                          on business travel.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             April 5, 2005

 Mr. Abercrombie introduced the following bill; which was referred to 
                    the Committee on Ways and Means

_______________________________________________________________________

                                 A BILL

 
To amend the Internal Revenue Code of 1986 to restore the deduction for 
the travel expenses of a taxpayer's spouse who accompanies the taxpayer 
                          on business travel.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. RESTORATION OF DEDUCTION FOR TRAVEL EXPENSES OF SPOUSE, ETC. 
              ACCOMPANYING TAXPAYER ON BUSINESS TRAVEL.

    (a) In General.--Subsection (m) of section 274 of the Internal 
Revenue Code of 1986 (relating to additional limitations on travel 
expenses) is amended by striking paragraph (3).
    (b) Effective Date.--The amendment made by this section shall apply 
to amounts paid or incurred after the date of the enactment of this 
Act.
                                 <all>
```
EXHIBIT 32.1





PHARMOS CORPORATION


SECTION 1350 CERTIFICATION





In connection with the quarterly report of PHARMOS CORPORATION, a Nevada corporation (the “Company”), on Form 10-Q for the quarter ended March 31, 2011, as filed with the Securities and Exchange Commission (the “Report”), I, ROBERT F. JOHNSTON, Executive Chairman (Principal Executive Officer) of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:





(1) the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and





(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.





This Certification has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission.





Date: April 28, 2011





By: /s/ Robert F. Johnston











A signed original of this written statement required by Section 906, or other document authenticating, acknowledging or otherwise adopting the signatures that appear in typed form within the electronic version of this written statement required by Section 906, has been provided to Pharmos Corporation and will be retained by Pharmos Corporation and furnished to the Securities and Exchange Commission or its staff upon request.
----

----

|   | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                                        |   |                    |   |
|---------------------------------------------|--------|-------------------------|--------|
| Date:    April 14, 2011 |   | /s/ William Elder       |   |
|                                        |   | William Elder           |   |
|                                        |   | Chief Executive Officer |   |

----
Keith Cavell REEDER, petitioner, v. UNITED STATES.

No. 12-8664.

Supreme Court of the United States

June 27, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Fifth Circuit denied.
In re Antonio COLBERT, petitioner.

No. 13-5726.

Supreme Court of the United States

Nov. 12, 2013.

Petition for rehearing denied.
#### The City of St. Louis, *Appellant,*v. White.

The case of *The City of St. Louis v. Marchel, ante,*p. 475, affirmed.

Appeal dismissed.

*Levereti Bell*for appellant.

*Wm. A. Bisse*for respondent.

Bakclay, J.

In this cause the city has appealed from a judgment of the St. Louis court of criminal correction in favor of the defendant. The same facts are *478presented as those considered by this court in the case of *City of St. Louis v.*Marchel, ante, p. 475, and in accordance with the ruling therein made the appeal by the plaintiff in this case is dismissed.

All concur.
Exhibit 31.1CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002I, Earl L Yager, as Chief Executive Officer of CHAD Therapeutics, Inc. (the “registrant”), herebycertify that:(1) I have reviewed this quarterly report on Form 10-Q of CHAD Therapeutics, Inc.; (2) Based on my knowledge, this quarterly report does not contain any untrue statement of amaterial fact or omit to state a material fact necessary to make the statements made, in lightof the circumstances under which such statements were made, not misleading with respect to theperiod covered by this quarterly report; (3) Based on my knowledge, the financial statements, and other financial information included inthis quarterly report, fairly present in all material respects the financial condition,results of operations and cash flows of the registrant as of, and for, the periods presentedin this quarterly report; (4) The registrant’s other certifying officer and I are responsible for establishing andmaintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and15d-15(e)) for the registrant and have: (a) designed such disclosure controls and procedures, or caused such disclosurecontrols and procedures to be designed under our supervision, to ensure that materialinformation relating to the registrant, including its consolidated subsidiaries, is madeknown to us by others within those entities, particularly during the period in which thisquarterly report is being prepared;  (b) Paragraph omitted;  (c) evaluated the effectiveness of the registrant’s disclosure controls and proceduresand presented in this report our conclusions about the effectiveness of the disclosurecontrols and procedures, as of the end of the period covered by this report based on suchevaluation; and  (d) disclosed in this report any change in the registrant’s internal control overfinancial reporting that occurred during the registrant’s most recent fiscal quarter (theregistrant’s fourth fiscal quarter in the case of an annual report) that has materiallyaffected, or is reasonably likely to materially affect, the registrant’s internal controlover financial reporting; and(5) The registrant’s other certifying officer and I have disclosed, based on our most recentevaluation of internal control over financial reporting, to the registrant’s auditors and theaudit committee of registrant’s board of directors (or persons performing the equivalentfunctions): (a) all significant deficiencies and material weaknesses in the design or operation ofinternal control over financial reporting which are reasonably likely to adversely affectthe registrant’s ability to record, process, summarize and report financial information;and  (b) any fraud, whether or not material, that involves management or other employees whohave a significant role in the registrant’s internal control over financial reporting.         Date: August 14, 2007 /s/ Earl L. Yager   Earl L. Yager        Chief Executive Officer of CHAD Therapeutics, Inc.
EXHIBIT 32.2





PHARMOS CORPORATION


SECTION 1350 CERTIFICATION








In connection with the quarterly report of PHARMOS CORPORATION, a Nevada corporation (the “Company”), on Form 10-Q for the quarter ended March 31, 2010, as filed with the Securities and Exchange Commission (the “Report”), I, S. COLIN NEILL, Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:





(1) the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and





(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.





This Certification has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission.





Date: May 12, 2010





By: /s/ S. Colin Neill





A signed original of this written statement required by Section 906, or other document authenticating, acknowledging or otherwise adopting the signatures that appear in typed form within the electronic version of this written statement required by Section 906, has been provided to Pharmos Corporation and will be retained by Pharmos Corporation and furnished to the Securities and Exchange Commission or its staff upon request.
UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF INDIANA 

FORT WAYNE DIVISION 

 

UNITED STATES OF AMERICA ) 

 ) 

 v. ) CASE NO.: 1:15-CR-44-TLS-1 

 ) 

COREY S. EAVES ) 

 

ORDER ACCEPTING FINDINGS AND RECOMMENDATION 

 This matter is before the Court on the Findings and Recommendation of the United States 

Magistrate Judge [ECF No. 33], filed on February 26, 2016. The Defendant has waived objection 

to the Findings and Recommendation, and the Court, being duly advised, adopts the Findings 

and Recommendation [ECF No. 33] in its entirety and accepts the recommended disposition. 

Subject to this Court’s consideration of the Plea Agreement pursuant to Federal Rule of Criminal 

Procedure 11(c), the plea of guilty to the offense charged in Count One (1) of the single count 

Indictment is hereby accepted, and the Defendant is adjudged guilty of such offense. 

 The notice of sentencing and pre-sentence scheduling deadlines will be issued by separate 

order.

SO ORDERED on March 15, 2016. 

 s/ Theresa L. Springmann 

 THERESA L. SPRINGMANN 

 UNITED STATES DISTRICT COURT
UNITED STATES COURT OF APPEALS FOR THE SEVENTH CIRCUIT

Everett McKinley Dirksen UnitedStatesCourthouse

 Room 2722 - 219 S. Dearborn Street

 Chicago, Illinois 60604

Office of the Clerk

Phone: (312) 435-5850

www.ca7.uscourts.gov

NOTICE OF ISSUANCE OF MANDATE

March 24, 2015

To: Robert N. Trgovich

 UNITED STATES DISTRICT COURT

 Northern District of Indiana

 Hammond , IN 46320-0000

No. 14-1959

MIR S. IQBAL, 

Plaintiff - Appellant

v.

TEJASKUMAR M. PATEL, et al.,

Defendants - Appellees

 Originating Case Information:

 District Court No: 2:12-cv-00056-JTM-APR

Northern District of Indiana, Hammond Division

District Judge James T. Moody

Herewith is the mandate of this court in this appeal, along with the Bill of Costs, if any. A

certified copy of the opinion/order of the court and judgment, if any, and any direction as to

costs shall constitute the mandate.

 AMOUNT OF BILL OF COSTS (do not

include the $):

 528.40

 DATE OF MANDATE OR AGENCY

CLOSING LETTER ISSUANCE: 03/24/2015

USDC IN/ND case 2:12-cv-00056-JTM-APR document 50 filed 03/24/15 page 1 of 2 Case: 14-1959 Document: 00712495120 Filed: 03/24/2015 Pages: 2
 RECORD ON APPEAL STATUS: No record to be returned

NOTE TO COUNSEL:

If any physical and large documentary exhibits have been filed in the above-entitled cause, they are

to be withdrawn ten (10) days from the date of this notice. Exhibits not withdrawn during this period

will be disposed of.

Please acknowledge receipt of these documents on the enclosed copy of this notice.

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Received above mandate and record, if any, from the Clerk, U.S. Court of Appeals for the

Seventh Circuit.

Date: Received by:

_________________________ ____________________________________

form name: c7_Mandate(form ID: 135)

USDC IN/ND case 2:12-cv-00056-JTM-APR document 50 filed 03/24/15 page 2 of 2 Case: 14-1959 Document: 00712495120 Filed: 03/24/2015 Pages: 2
Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Justice Drug Enforcement Administration [Docket No. DEA-854]
 AGENCY: Drug Enforcement Administration, Justice.
 ACTION: Notice of application.
 SUMMARY: Xcelience has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
 DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before July 19, 2021. Such persons may also file a written request for a hearing on the application on or before July 19, 2021.
 ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.


SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on April 28, 2021, Xcelience, 4901 West Grace Street, Tampa, Florida 33607-3805, applied to be registered as an importer of the following basic class(es) of controlled substance(s): Controlled substance
Drug code
SchedulePsilocybin
7437
I
 The company plans to import drug code 7437 (Psilocybin) as finished dosage form for clinical trials, research, and analytical purposes. Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale. William T. McDermott, Assistant Administrator.


[FR Doc. 2021-12816 Filed 6-16-21; 8:45 am] BILLING CODE P
Federal Deposit Insurance Corporation

550 17th St. NW Washington DC, 20429 Deputy to the Chairman & Chief Financial Officer

February 7, 2005

Mr. David M. Walker 

Comptroller General of the United States

U. S. Government Accountability Office

441 G Street, NW

Washington, DC 20548

Re: FDIC Management Response on the 

GAO 2004 Financial Statements Audit Report

Dear Mr. Walker:

Thank you for the opportunity to comment on the U.S. Government Accountability Office’s

(GAO) draft audit report titled, Financial Audit: Federal Deposit Insurance Corporation

Funds’ 2004 and 2003 Financial Statements, GAO-05-281. The report presents GAO’s 

opinions on the calendar year 2004 financial statements of the Bank Insurance Fund (BIF),

the Savings Association Insurance Fund (SAIF), and the Federal Savings and Loan

Insurance Corporation Resolution Fund (FRF). The report also presents GAO’s opinion 

on the effectiveness of FDIC’s internal controls as of December 31, 2004, and GAO’s 

evaluation of FDIC’s compliance with applicable laws and regulations.

We are pleased to accept GAO’s unqualified opinions on the BIF, SAIF, and FRF financial

statements and to note that there were no material weaknesses identified during the 2004

audits. The GAO reported that the funds’ financial statements were presented fairly, 

in all material respects, in conformity with U.S. generally accepted accounting principles;

FDIC had effective internal control over financial reporting and compliance with laws and

regulations; and there were no instances of noncompliance with laws and regulations that

were tested.

Also, we are pleased that GAO recognized the significant improvements that have 

been made during the past year and acknowledged our progress in fully implementing 

a comprehensive information security (IS) program. As always, management is committed 

to ensuring the continued success of an effective and strong IS program. We will remain

focused on accomplishing the work needed to face the new security challenges in the 

coming year. 

If you have any questions or concerns, please let me know.

Sincerely,

Steven O. App

Deputy to the Chairman and Chief Financial Officer

99

Appendix I
**EXHIBIT 32.2**

**CERTIFICATION OF THE PRINCIPAL ACCOUNTING OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

          I, Zong Yun Zhou, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Amendment to Quarterly Report of SORL AUTO PARTS, INC. on Form 10Q/A for the fiscal quarter ended March 31, 2006 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of SORL AUTO PARTS, INC.

| Date:  August 15, 2006 | /s/ Zong Yun   Zhou       |
|-----------------------------|---------------------------|
|                        |                           |
|                        | Zong Yun   Zhou           |
|                        | Chief   Financial Officer |
|                        |                      |
|                             |                           |
```

[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1791 Introduced in House (IH)]

109th CONGRESS
  1st Session
                                H. R. 1791

To amend the Internal Revenue Code of 1986 to reduce the rate of tax on 
                distilled spirits to its pre-1985 level.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             April 21, 2005

    Mr. Lewis of Kentucky (for himself, Mr. Chandler, Mr. Rogers of 
    Kentucky, Mr. Whitfield, Mr. Davis of Kentucky, Mr. Tanner, Mr. 
 Hensarling, Mr. Jenkins, Mr. Simmons, Mr. Terry, Mrs. Jo Ann Davis of 
 Virginia, Mr. Petri, Mr. Ney, Mr. Kennedy of Minnesota, Mr. Miller of 
Florida, Mr. Coble, Mr. Doyle, Mr. Wilson of South Carolina, Mr. Burton 
   of Indiana, Mr. Bonilla, Mr. Foley, Mr. Paul, Mr. Radanovich, Mr. 
     Boehner, Mr. Sessions, Mr. Shaw, Mr. Towns, Mr. Cardoza, Mr. 
Cunningham, Mr. Hastings of Washington, Mr. Rogers of Michigan, and Mr. 
  Culberson) introduced the following bill; which was referred to the 
                      Committee on Ways and Means

_______________________________________________________________________

                                 A BILL

 
To amend the Internal Revenue Code of 1986 to reduce the rate of tax on 
                distilled spirits to its pre-1985 level.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. REDUCTION IN RATE OF TAX ON DISTILLED SPIRITS TO PRE-1985 
              LEVELS.

    (a) In General.--Paragraph (1) of section 5001(a) of the Internal 
Revenue Code of 1986 (relating to imposition, rate, and attachment of 
tax) is amended by striking ``$13.50'' and inserting ``$10.50''.
    (b) Conforming Amendments.--
            (1) Subsection (a) of section 5010 of such Code is amended 
        by striking ``$13.50'' each place it appears and inserting 
        ``$10.50''.
            (2) Subsection (f) of section 7652 of such Code is hereby 
        repealed.
    (c) Effective Date.--The amendments made by this section shall take 
effect on the first date that the Director of the Office of Management 
and Budget projects that--
            (1) there is a Federal budget surplus (determined without 
        regard to the income and expenditures of the social security 
        trust funds) for the fiscal year that includes such date, and
            (2) such surplus is not less than the aggregate revenue 
        reductions during such period resulting from the amendments 
        made by this Act.
                                 <all>
```
[Federal Register Volume 60, Number 101 (Thursday, May 25, 1995)]
[Notices]
[Page 27795]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-12843]



-----------------------------------------------------------------------


DEPARTMENT OF LABOR

Advisory Council on Employee Welfare and Pension Benefit Plans; 
Notice of Meeting

    Pursuant to the authority contained in Section 512 of the Employee 
Retirement Security Act of 1974 (ERISA), 29 U.S.C. 1142, a public 
meeting of the Working Group on Real Estate Investment of the Advisory 
Council on Employee Welfare and Pension Benefit Plans will be held from 
1:00 p.m. until 3:30 noon, Tuesday, June 13, 1995, in Suite S-3215 A-B, 
U.S. Department of Labor Building, Third and Constitution Avenue, N.W., 
Washington, D.C. 20210.
    This work group was formed by the Advisory Council to study issues 
relating to real estate investment, focusing on real estate investment 
advisor practices and real estate valuations.
    The purpose of the June 13 meeting is to receive testimony from 
invited persons addressing the following questions: (1) Is current 
regulatory oversight of real estate investment advisors adequate?; (2) 
Is additional regulation needed beyond the Securities and Exchange 
Commission registration guidelines?; and (3) Would self-regulation of 
real estate investment advisors be better? The work group will hear 
testimony from a plan sponsor, a pension consultant dealing with real 
estate, a Department of Labor representative, a real estate investment 
manager, and a lawyer with experience in real estate fee structures.
    The work group will also take testimony and/or submissions from 
employee representatives, employer representatives and other interested 
individuals and groups regarding the subject matter. Individuals or 
representatives of organizations wishing to address the work group 
should submit a written request on or before June 8, 1995 to Linda R. 
Jackson, Acting Executive Secretary, ERISA Advisory Council, U.S. 
Department of Labor, Suite N-5677, 200 Constitution Avenue, N.W., 
Washington, D.C. 20210. Oral presentations will be limited to ten (10) 
minutes, but witnesses may submit an extended statement for the record.
    Organizations or individuals may also submit statements for the 
record without testifying. Twenty (20) copies of such statement should 
be sent to the Executive Secretary of the Advisory Council at the above 
address. Papers will be accepted and included in the record of the 
meeting if received on or before June 8, 1995.
Olena Berg,
Assistant Secretary, Pension and Welfare Benefits Administration.
[FR Doc. 95-12843 Filed 5-24-95; 8:45 am]
BILLING CODE 4510-29-M